Overview
DFTX market data
Price History
DFTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.70 – $49.70 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6B · P/B 4.04.
Company News
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90Benzinga · Aug 13, 2026, 6:00 PM
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64Benzinga · Aug 13, 2026, 4:33 PM
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66Benzinga · Aug 13, 2026, 3:07 PM
Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72Benzinga · Aug 13, 2026, 1:32 PM
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75Benzinga · Aug 13, 2026, 10:20 AM
Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $66Benzinga · Aug 12, 2026, 7:14 PM
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'Benzinga · Aug 12, 2026, 2:23 PM
8-K filing — Definium Therapeutics, Inc. (DFTX)SEC EDGAR · Aug 12, 2026, 12:05 PM
Definium Therapeutics shares are trading higher after the company announced topline results from the Phase 3 Voyage study met its primary and all key secondary endpointsBenzinga · Aug 12, 2026, 11:48 AM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Aug 12, 2026, 11:25 AM